Tuesday, May 22, 2012

Alvine targets Phase IIb celiac disease trial this year

The privately held San Carlos companyreported data Tuesday from a Phase IIa trial of its drug, called ALV-003, that it believes makes it the first mid-stage celiac disease study to meet predetermined goals. It plans to start a Phase IIb trial later this year.

No comments:

Post a Comment